Skip to content

Search

Showing results for "Childhood interstitial lung disease "

MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

A The Kids Research Institute Australia spin-off company has received $20 million from the Medical Research Commercialisation Fund to develop a promising new therapy for the treatment of Cystic Fibrosis.

Impaired airway epithelial cell responses from children with asthma to rhinoviral infection

Human rhinovirus infection delays repair and inhibits apoptotic processes in epithelial cells from non-asthmatic and asthmatic children

Environmental microbial exposure and protection against asthma

This article looks at the clinical implications of the research into microbial exposure & protection against asthma.

Prevention - what is the most promising approach?

This paper is an editorial comment by Professor Patrick Holt on the potential for developing early intervention strategies in children with allergies and asthma

Early immunological influences on asthma development: opportunities for early intervention

Early immunological influences on asthma development: opportunities for early intervention

COMBAT CF: A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis.

A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis

Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis

Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis Background: Neutrophil elastase is a significant risk factor for

The mechanism or mechanisms driving atopic asthma initiation: The infant respiratory microbiome moves to center stage

Although debate surrounding the mechanism or mechanisms governing this causal pathway remains intense, demonstration of the capacity of pretreatment...